Adlyxin vs Zepbound

Drug comparison

Last updated 2026-05-28 15:46 UTC

Adlyxin (lixisenatide) is a once-daily injection made by Sanofi for treating type 2 diabetes, while Zepbound (tirzepatide) is a once-weekly injection by Eli Lilly approved for obesity and obstructive sleep apnea. Both are given under the skin, but Adlyxin targets blood sugar control in diabetes, whereas Zepbound helps with weight management and sleep apnea.

AI summary of the sources below.

	Adlyxin	Zepbound
Active ingredient	lixisenatide	tirzepatide
Manufacturer	sanofi	eli-lilly
Route	subcutaneous injection	subcutaneous injection
FDA-approved for	type 2 diabetes	obesity, obstructive sleep apnea
Label updated	—	2026-04-22

Compare full details on the Adlyxin and Zepbound pages.